Development, Validation, and Subtype Analysis of a Predictive Model for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy

肥厚型心肌病患者房颤预测模型的建立、验证和亚型分析

阅读:2

Abstract

BACKGROUND: Atrial fibrillation (AF) is a major complication of hypertrophic cardiomyopathy (HCM) with significant prognostic implications. Current risk prediction models lack the integration of comprehensive cardiac magnetic resonance (CMR) metrics and subtype-specific analyses. METHODS: A retrospective study of 405 HCM patients (86 with AF) was performed from 2019 to 2024. After excluding highly correlated variables (|r| > 0.8), the cohort was split into training and validation sets in a 7:3 ratio. Least Absolute Shrinkage and Selection Operator (LASSO) regression and multivariable logistic regression analyses were used to identify predictors, with model performance assessed via receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis. Subgroup analyses were conducted for obstructive (HOCM) and non-obstructive (HNCM) subtypes. RESULTS: Independent predictors of AF in the overall HCM cohort included right atrial diameter anteroposterior (RAD anteroposterior: odds ratio (OR) = 1.819, 95% confidence interval (CI) 1.130-3.007; p = 0.016), left ventricular end-systolic volume (LVESV: OR = 0.978, 95% CI 0.963-0.991; p = 0.002), septal mitral annular plane systolic excursion (MAPSE septal: OR = 0.850, 95% CI 0.736-0.976; p = 0.023), tricuspid annular plane systolic excursion (TAPSE: OR = 0.919, 95% CI 0.852-0.987; p = 0.022), and maximum left atrial volume (MaxLAV: OR = 1.016, 95% CI 1.004-1.029; p = 0.010). The model achieved an area under the curve (AUC) value of 0.850 in the training set and an AUC of 0.861 in the validation set. The HOCM subtype predictors included septal MAPSE and left atrial ejection fraction (LAEF); meanwhile, the HNCM predictors included septal MAPSE, maximal left atrial volume (MaxLAV), and right atrial ejection fraction (RAEF). CONCLUSIONS: A validated multiparametric CMR model can accurately predict AF risk in HCM patients, with subtype-specific predictors enabling personalized monitoring and early intervention.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。